Women’s experiences are forgotten in research on childbirth and breastfeeding
Thomas Saïas, Professeur de psychologie, Université du Québec à Montréal (UQAM) / theconversation - Two studies in the field of perinatal care show how, in the areas of breastfeeding and obstetrics, science prioritizes risk and the baby at the expense of mothers’ well-being.
AI Summary: New analyses show that research into childbirth and breastfeeding repeatedly sidelines women's firsthand experiences, prioritizing clinical metrics over lived realities. Experts warn this gap limits understanding of postpartum challenges, skews policy and perpetuates poorer care. Calls are growing for qualitative measures, patient-centered outcomes and inclusive study designs that actually listen to mothers.
- Clinical and policy focus on fetus over mothers' care (3)
- Mothers’ experiences ignored in childbirth and breastfeeding research (4)
- Women’s pain and reproductive conditions dismissed by medicine (4)
- All Other Stories
Clinical and policy focus on fetus over mothers' care
Mothers’ experiences ignored in childbirth and breastfeeding research
Women’s pain and reproductive conditions dismissed by medicine
All Other Stories
License to deliver: Some midwives break the law to assist with home births
medicalxpress - In a midwife's suburban Atlanta home with a playground and chicken coop outside, Madie Collins lay on an examination table while the midwife measured her pregnant belly. Unlike at many a doctor's office, no crinkly paper sheet covered the table and no ant…
AI Summary: A growing number of midwives are reportedly supporting planned home births outside legal frameworks, knowingly operating without required licences. Regulators and health systems face a tricky balance between enforcing safety standards and meeting demand for community-based birthing options. Expect investigations, heated debates, and at least one bureaucrat suddenly very busy.
Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
Cyril Erameh / nature - Nature Medicine, Published online: 15 May 2026; doi:10.1038/s41591-026-04402-wAn open-label, randomized controlled phase 2 trial comparing favipiravir with ribavirin for the treatment of mild-to-moderate Lassa fever in Nigeria found that favipiravir was s…
AI Summary: An open-label, randomized Phase 2 trial of favipiravir for Lassa fever reported encouraging results, suggesting antiviral benefit where few options exist. The study offers early clinical proof-of-concept, especially important for endemic West African settings, and calls for larger trials to confirm efficacy, optimize dosing, and assess deployment logistics.